Sign in

Anyan Rama

Managing Director and Senior Equity Analyst at JPMorgan Chase & Co.

Anupam Rama is a Managing Director and Senior Equity Analyst at JPMorgan Chase & Co., where he specializes in U.S. healthcare sector research, with a particular focus on biotechnology and pharmaceuticals. He covers a broad universe of companies, including Vera Therapeutics, Neurocrine Biosciences, and numerous other U.S.-listed biotech firms, and has delivered top calls such as a 695% return on Vera Therapeutics. Over his career, Rama has issued more than 850 stock ratings, achieving a success rate of approximately 40% with an average return per recommendation ranging from -1.9% to over 8%, depending on the metrics and platform. He has advanced from prior roles to become Managing Director at JPMorgan and holds professional securities licenses as required for lead sell-side research analysts.

Anyan Rama's questions to Ultragenyx Pharmaceutical (RARE) leadership

Question · Q3 2025

Anyan Rama inquired about the expected enrollment curve for the Aurora supportive study for GTX-102 in Angelman syndrome, asking how it might compare to the enrollment observed in the pivotal ASPIRE trial.

Answer

Howard Horn, Chief Financial Officer, anticipated that the Aurora trial would enroll quickly due to high patient interest for its open-label design, contrasting with the sham-controlled ASPIRE study. He noted its importance for gathering data across a wider array of genotypes.

Ask follow-up questions

Fintool

Fintool can predict Ultragenyx Pharmaceutical logo RARE's earnings beat/miss a week before the call

Let Fintool AI Agent track Anyan Rama for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free